Data Insights

XTX-301 by Gilead Sciences for Triple-Negative Breast Cancer (TNBC): Likelihood of Approval

XTX-301 is under clinical development by Gilead Sciences and currently in Phase II for Triple-Negative Breast Cancer (TNBC). According to...

Likelihood of Approval and Phase Transition Success Rate Model - XTX-301 in Triple-Negative Breast Cancer (TNBC)

Data Insights

XTX-301 by Gilead Sciences for Head And Neck Squamous Cell Carcinoma (HNSC): Likelihood of Approval

XTX-301 is under clinical development by Gilead Sciences and currently in Phase II for Head And Neck Squamous Cell Carcinoma...

Likelihood of Approval and Phase Transition Success Rate Model - XTX-301 in Head And Neck Squamous Cell Carcinoma (HNSC)

Data Insights

XTX-301 by Gilead Sciences for Non-Small Cell Lung Cancer: Likelihood of Approval

XTX-301 is under clinical development by Gilead Sciences and currently in Phase II for Non-Small Cell Lung Cancer. According to...

Likelihood of Approval and Phase Transition Success Rate Model - XTX-301 in Non-Small Cell Lung Cancer

Data Insights

XTX-301 by Gilead Sciences for Endometrial Cancer: Likelihood of Approval

XTX-301 is under clinical development by Gilead Sciences and currently in Phase II for Endometrial Cancer. According to GlobalData, Phase...

Likelihood of Approval and Phase Transition Success Rate Model - XTX-301 in Endometrial Cancer

Data Insights

XTX-301 by Gilead Sciences for T-Cell Lymphomas: Likelihood of Approval

XTX-301 is under clinical development by Gilead Sciences and currently in Phase II for T-Cell Lymphomas. According to GlobalData, Phase...

Likelihood of Approval and Phase Transition Success Rate Model - XTX-301 in T-Cell Lymphomas

Data Insights

XTX-301 by Gilead Sciences for Solid Tumor: Likelihood of Approval

XTX-301 is under clinical development by Gilead Sciences and currently in Phase II for Solid Tumor. According to GlobalData, Phase...

Likelihood of Approval and Phase Transition Success Rate Model - XTX-301 in Solid Tumor

Data Insights

XTX-301 by Gilead Sciences for Pancreatic Cancer: Likelihood of Approval

XTX-301 is under clinical development by Gilead Sciences and currently in Phase II for Pancreatic Cancer. According to GlobalData, Phase...

Likelihood of Approval and Phase Transition Success Rate Model - XTX-301 in Pancreatic Cancer

Data Insights

XTX-301 by Gilead Sciences for Melanoma: Likelihood of Approval

XTX-301 is under clinical development by Gilead Sciences and currently in Phase II for Melanoma. According to GlobalData, Phase II...

Likelihood of Approval and Phase Transition Success Rate Model - XTX-301 in Melanoma

Data Insights

XTX-301 by Gilead Sciences for Colorectal Cancer: Likelihood of Approval

XTX-301 is under clinical development by Gilead Sciences and currently in Phase II for Colorectal Cancer. According to GlobalData, Phase...

Likelihood of Approval and Phase Transition Success Rate Model - XTX-301 in Colorectal Cancer

Data Insights

XTX-301 by Gilead Sciences for Prostate Cancer: Likelihood of Approval

XTX-301 is under clinical development by Gilead Sciences and currently in Phase II for Prostate Cancer. According to GlobalData, Phase...

Likelihood of Approval and Phase Transition Success Rate Model - XTX-301 in Prostate Cancer

Data Insights

XTX-301 by Gilead Sciences for Ovarian Cancer: Likelihood of Approval

XTX-301 is under clinical development by Gilead Sciences and currently in Phase II for Ovarian Cancer. According to GlobalData, Phase...

Likelihood of Approval and Phase Transition Success Rate Model - XTX-301 in Ovarian Cancer